A. Yu. Anokhin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. Yu. Anokhin has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Alexey A. Rumyantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Tatiana E. Tikhomirova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Sergey L. Gutorov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - A. N. Lud
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Sergei A. Tjulandin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications A. A. Rumyantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 35-43
Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population
Background . Introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and / or HRD-positive EOC patients in real-world practice setting. Patients and methods. We enrolled patients with FIGO stage III–IV high-grade serous or endometrioid EOC with BRCA1 / 2 mutations and / or HRD-positive status with complete or partial response to frontline therapy, who were treated in 2014–2024. Main objective of this trial was to compare progression-free survival (PFS) of HRD+ / BRCA-mutant advanced EOC patients treated with or without maintenance olaparib in well-balanced treatment arms. Cardinality matching was considered to ensure balancing of the study arms with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, platinum-free interval duration after frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was PFS. Results. Cardinality matching with 1:1 ratio resulted in 282 matched patients for the analysis. Groups were well balanced in all baseline characteristics. Median age in both treatment arms was 50 years with no differences in patients' age, surgical outcomes, prevalence of BRCA-mutated or HRD-positive disease and response to initial platinum-based therapy. With a median follow up of 37.2 mo. median PFS was 38.0 in the olaparib arm and 13.7 mo. in the control arm, respectively (HR 0.32; 95 % CI 0.23–0.43; p < 0.001). Estimated 3-year PFS was 50.9 % and 11.5 %, respectively. Median PFS2 was 49.5 mo. in the olaparib arm compared to 34.3 mo. in the control arm (HR 0.58; 95 % CI 0.39–0.85; p = 0.005). Conclusion. This study confirms the benefits of olaparib maintenance therapy in patients with HRD-positive and / or BRCA-mutated advanced EOC in real-world setting.
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 35-43
Open AccessFrontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population
Background . Introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and / or HRD-positive EOC patients in real-world practice setting. Patients and methods. We enrolled patients with FIGO stage III–IV high-grade serous or endometrioid EOC with BRCA1 / 2 mutations and / or HRD-positive status with complete or partial response to frontline therapy, who were treated in 2014–2024. Main objective of this trial was to compare progression-free survival (PFS) of HRD+ / BRCA-mutant advanced EOC patients treated with or without maintenance olaparib in well-balanced treatment arms. Cardinality matching was considered to ensure balancing of the study arms with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, platinum-free interval duration after frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was PFS. Results. Cardinality matching with 1:1 ratio resulted in 282 matched patients for the analysis. Groups were well balanced in all baseline characteristics. Median age in both treatment arms was 50 years with no differences in patients' age, surgical outcomes, prevalence of BRCA-mutated or HRD-positive disease and response to initial platinum-based therapy. With a median follow up of 37.2 mo. median PFS was 38.0 in the olaparib arm and 13.7 mo. in the control arm, respectively (HR 0.32; 95 % CI 0.23–0.43; p < 0.001). Estimated 3-year PFS was 50.9 % and 11.5 %, respectively. Median PFS2 was 49.5 mo. in the olaparib arm compared to 34.3 mo. in the control arm (HR 0.58; 95 % CI 0.39–0.85; p = 0.005). Conclusion. This study confirms the benefits of olaparib maintenance therapy in patients with HRD-positive and / or BRCA-mutated advanced EOC in real-world setting.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 67-74
Systemic drug therapy for metastatic uterine leiomyosarcoma: treatment results from real clinical practice
Background. Currently, adjuvant chemotherapy of choice after surgical treatment of uterine leiomyosarcoma is doxorubicin. The same approach is used for the 1st line of systemic drug therapy in patients with initially metastatic process, or those who have not previously received adjuvant treatment with anthracyclines. Disseminated forms of metastatic leiomyosarcoma are characterized by unfavorable prognosis, and the options for potentially effective drug treatments are limited. Aim. To evaluate the efficacy of 1st and 2nd line chemotherapy regimens for uterine leiomyosarcoma in a population of patients in real clinical practice. Materials and methods. The retrospective analysis included 43 patients with histologically verified uterine leiomyosarcoma. The study included patients with primarily localized forms of the disease, who underwent surgical treatment at the 1st stage (with or without adjuvant chemotherapy), and patients with initially metastatic disease. All patients had a history of 1–2 lines of systemic drug therapy due to disease progression. Results. The analysis included 43 patients who underwent treatment at the N. N. Blokhin National Medical Research Center of Oncology between 2021 and 2024. The efficacy of the 1st line was assessed in 35 (81.4 %) patients: the objective response rate reached 17.6 %, and median progression-free survival from the start of the 1st line was 7.4 months. The efficacy of 2nd line of therapy was assessed in 18 (41.9 %) patients: the objective response rate was 11.1 %, median progression-free survival from the start of the 1st line to progression after the 2nd line was 13.2 months, and median progression-free survival from the start of the 2nd line to progression after it was 3.3 months. Conclusion. Analysis of the efficacy of systemic drug therapy for uterine leiomyosarcoma in real clinical practice demonstrates comparable long-term treatment results with data from international literature. Further study of the efficacy of combined adjuvant and 1st line therapy regimens seems promising.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 67-74
Systemic drug therapy for metastatic uterine leiomyosarcoma: treatment results from real clinical practice
Background. Currently, adjuvant chemotherapy of choice after surgical treatment of uterine leiomyosarcoma is doxorubicin. The same approach is used for the 1st line of systemic drug therapy in patients with initially metastatic process, or those who have not previously received adjuvant treatment with anthracyclines. Disseminated forms of metastatic leiomyosarcoma are characterized by unfavorable prognosis, and the options for potentially effective drug treatments are limited. Aim. To evaluate the efficacy of 1st and 2nd line chemotherapy regimens for uterine leiomyosarcoma in a population of patients in real clinical practice. Materials and methods. The retrospective analysis included 43 patients with histologically verified uterine leiomyosarcoma. The study included patients with primarily localized forms of the disease, who underwent surgical treatment at the 1st stage (with or without adjuvant chemotherapy), and patients with initially metastatic disease. All patients had a history of 1–2 lines of systemic drug therapy due to disease progression. Results. The analysis included 43 patients who underwent treatment at the N. N. Blokhin National Medical Research Center of Oncology between 2021 and 2024. The efficacy of the 1st line was assessed in 35 (81.4 %) patients: the objective response rate reached 17.6 %, and median progression-free survival from the start of the 1st line was 7.4 months. The efficacy of 2nd line of therapy was assessed in 18 (41.9 %) patients: the objective response rate was 11.1 %, median progression-free survival from the start of the 1st line to progression after the 2nd line was 13.2 months, and median progression-free survival from the start of the 2nd line to progression after it was 3.3 months. Conclusion. Analysis of the efficacy of systemic drug therapy for uterine leiomyosarcoma in real clinical practice demonstrates comparable long-term treatment results with data from international literature. Further study of the efficacy of combined adjuvant and 1st line therapy regimens seems promising.
- Open Access
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 88-96
dd-MVAC as neoadjuvant chemotherapy for muscle-invasive bladder cancer: a single-center study
Aim. To evaluate the efficacy, safety, and feasibility of dd-MVAC (methotrexate, vinblastine, doxorubicin, cyclophosphamide) chemotherapy in real-world clinical practice. Materials and methods. Patients were enrolled between September 2022 and May 2025. They were scheduled to receive six cycles of neoadjuvant dd-MVAC chemotherapy, supported by granulocyte colony-stimulating factor from day 4 to day 9 of each cycle, repeated every two weeks. Eligible patients had urothelial bladder cancer staged as cT2–4a, N0–3, M0, with creatinine clearance of ≥50 mL/min. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included toxicity, the number of treatment cycles completed, and pathological response. Results. The study included 40 patients. Of these, 87 % (n = 35) completed six cycles of dd-MVAC, while 8 % (n = 3) and 5 % (n = 2) completed five and four cycles, respectively. Full protocol drug doses were administered to 57 % of patients (n = 23), while a 15 % dose reduction was required in 43 % (n = 17). The majority of these dose reductions (59 %, n = 10) were implemented after the fifth cycle. The most frequent grade 3 adverse events (per Common Terminology Criteria for Adverse Events (CTCAE) v.5.0) were hematological: neutropenia in 40 % (n = 16), anemia in 10 % (n = 4), and thrombocytopenia in 10 % (n = 4). One fatal case of febrile neutropenia occurred. The most common grade 1–2 adverse event was asthenia reported in 80 % (n = 32) of patients. Surgical treatment was performed in 80 % (n = 32) of the cohort. Cystectomy was conducted in 91 % (n = 29) of these surgical patients, while organ-preserving surgery was performed in 9 % (n = 3). A complete pathological response (ypT0pN0) was achieved in 53 % (n = 17) of surgically treated patients, and downstaging to ypT3pN0 was observed in 9 % (n = 3). Disease stabilization was reported in the remaining 38 % (n = 12). No significant decline in renal function was observed; median glomerular filtration rate was 80.4 mL/min/1.73 m2 pre-treatment and 89.1 mL/min/1.73 m2 post-treatment. Conclusion. The dd-MVAC regimen is an effective and feasible neoadjuvant therapy for muscle-invasive bladder cancer, enabling the majority of patients to complete the full preoperative course of chemotherapy.
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 88-96
Open Accessdd-MVAC as neoadjuvant chemotherapy for muscle-invasive bladder cancer: a single-center study
Aim. To evaluate the efficacy, safety, and feasibility of dd-MVAC (methotrexate, vinblastine, doxorubicin, cyclophosphamide) chemotherapy in real-world clinical practice. Materials and methods. Patients were enrolled between September 2022 and May 2025. They were scheduled to receive six cycles of neoadjuvant dd-MVAC chemotherapy, supported by granulocyte colony-stimulating factor from day 4 to day 9 of each cycle, repeated every two weeks. Eligible patients had urothelial bladder cancer staged as cT2–4a, N0–3, M0, with creatinine clearance of ≥50 mL/min. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included toxicity, the number of treatment cycles completed, and pathological response. Results. The study included 40 patients. Of these, 87 % (n = 35) completed six cycles of dd-MVAC, while 8 % (n = 3) and 5 % (n = 2) completed five and four cycles, respectively. Full protocol drug doses were administered to 57 % of patients (n = 23), while a 15 % dose reduction was required in 43 % (n = 17). The majority of these dose reductions (59 %, n = 10) were implemented after the fifth cycle. The most frequent grade 3 adverse events (per Common Terminology Criteria for Adverse Events (CTCAE) v.5.0) were hematological: neutropenia in 40 % (n = 16), anemia in 10 % (n = 4), and thrombocytopenia in 10 % (n = 4). One fatal case of febrile neutropenia occurred. The most common grade 1–2 adverse event was asthenia reported in 80 % (n = 32) of patients. Surgical treatment was performed in 80 % (n = 32) of the cohort. Cystectomy was conducted in 91 % (n = 29) of these surgical patients, while organ-preserving surgery was performed in 9 % (n = 3). A complete pathological response (ypT0pN0) was achieved in 53 % (n = 17) of surgically treated patients, and downstaging to ypT3pN0 was observed in 9 % (n = 3). Disease stabilization was reported in the remaining 38 % (n = 12). No significant decline in renal function was observed; median glomerular filtration rate was 80.4 mL/min/1.73 m2 pre-treatment and 89.1 mL/min/1.73 m2 post-treatment. Conclusion. The dd-MVAC regimen is an effective and feasible neoadjuvant therapy for muscle-invasive bladder cancer, enabling the majority of patients to complete the full preoperative course of chemotherapy.
- Open Access
- 2 May 2024
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 14 (1) , 62-71
Efficacy of total neoadjuvant chemotherapy in the FLOT regimen in patients with locally advanced gastric and gastroesophageal junction: results of a phase II study
Background. The established approach notably improving the therapeutic outcomes for locally advanced gastric cancer and gastroesophageal junction cancer, presently entails the amalgamation of perioperative chemotherapy aligned with the FLOT protocol and surgical intervention. However, this approach harbors limitations, as only half of the patient cohort successfully completes the entire prescribed course of drug therapy. The potential solution to this problem lies in the complete transfer of the chemotherapy volume to the preoperative period and the execution of total neoadjuvant chemotherapy with FLOT regimen.Aim. Aim is to conduct a comparative assessment of the efficacy and safety between total neoadjuvant and perioperative chemotherapy with FLOT regimen for patients with locally advanced gastric cancer and gastroesophageal junction cancer.Materials and methods. In a retrospective study we enrolled patients with histologically confirmed locally advanced gastric cancer and gastroesophageal junction cancer meeting clinical stage criteria T2–4 and N0–3, without of distant metastases, treated between 2014 and 2020 at Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation and Moscow City Oncologic Hospital No. 62 Department of Healthcare of Moscow. Participants in the control group underwent 8 courses of perioperative chemotherapy (4 preoperatively and 4 postoperatively), while those in the experimental group received 8 courses of total neoadjuvant chemotherapy. Both groups received drug therapy according to the FLOT protocol: 5-fluorouracil 2600 mg/m2 , intravenous drip, over 24 hours, leucovorin 200 mg/m2 , intravenous drip, oxaliplatin 85 mg/m2 , intravenous drip, docetaxel 50 mg/m2 , intravenous drip, on day 1, with a 14-day intercourse interval. The primary endpoint was one-year progression-free survival.Results. In the study included 187 patients. Participants were divided into two groups: 95 in the total neoadjuvant chemotherapy group and 92 in the perioperative chemotherapy group. The one-year progression-free survival was higher in the total neoadjuvant chemotherapy group at 79 %, compared to 68 % in the perioperative chemotherapy group (HR 0.54, 95 % confidence interval 0.32–0.9, p = 0.02). Median disease-free survival was 27.2 and 19.5 months in the neoadjuvant and perioperative chemotherapy groups, respectively. The tolerability of the entire planned drug treatment regimen was superior in the total neoadjuvant chemotherapy group, reaching 88.4 %, as opposed to 57.6 % in the perioperative chemotherapy group (p = 0.0001).Conclusion. Among patients with locally advanced gastric cancer and gastroesophageal junction cancer, the application of total neoadjuvant chemotherapy according to the FLOT protocol, administered over 8 courses, demonstrated enhanced one-year progression-free survival and improved tolerability of the entire planned treatment regimen.
- 2 May 2024
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 14 (1) , 62-71
Open AccessEfficacy of total neoadjuvant chemotherapy in the FLOT regimen in patients with locally advanced gastric and gastroesophageal junction: results of a phase II study
Background. The established approach notably improving the therapeutic outcomes for locally advanced gastric cancer and gastroesophageal junction cancer, presently entails the amalgamation of perioperative chemotherapy aligned with the FLOT protocol and surgical intervention. However, this approach harbors limitations, as only half of the patient cohort successfully completes the entire prescribed course of drug therapy. The potential solution to this problem lies in the complete transfer of the chemotherapy volume to the preoperative period and the execution of total neoadjuvant chemotherapy with FLOT regimen.Aim. Aim is to conduct a comparative assessment of the efficacy and safety between total neoadjuvant and perioperative chemotherapy with FLOT regimen for patients with locally advanced gastric cancer and gastroesophageal junction cancer.Materials and methods. In a retrospective study we enrolled patients with histologically confirmed locally advanced gastric cancer and gastroesophageal junction cancer meeting clinical stage criteria T2–4 and N0–3, without of distant metastases, treated between 2014 and 2020 at Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation and Moscow City Oncologic Hospital No. 62 Department of Healthcare of Moscow. Participants in the control group underwent 8 courses of perioperative chemotherapy (4 preoperatively and 4 postoperatively), while those in the experimental group received 8 courses of total neoadjuvant chemotherapy. Both groups received drug therapy according to the FLOT protocol: 5-fluorouracil 2600 mg/m2 , intravenous drip, over 24 hours, leucovorin 200 mg/m2 , intravenous drip, oxaliplatin 85 mg/m2 , intravenous drip, docetaxel 50 mg/m2 , intravenous drip, on day 1, with a 14-day intercourse interval. The primary endpoint was one-year progression-free survival.Results. In the study included 187 patients. Participants were divided into two groups: 95 in the total neoadjuvant chemotherapy group and 92 in the perioperative chemotherapy group. The one-year progression-free survival was higher in the total neoadjuvant chemotherapy group at 79 %, compared to 68 % in the perioperative chemotherapy group (HR 0.54, 95 % confidence interval 0.32–0.9, p = 0.02). Median disease-free survival was 27.2 and 19.5 months in the neoadjuvant and perioperative chemotherapy groups, respectively. The tolerability of the entire planned drug treatment regimen was superior in the total neoadjuvant chemotherapy group, reaching 88.4 %, as opposed to 57.6 % in the perioperative chemotherapy group (p = 0.0001).Conclusion. Among patients with locally advanced gastric cancer and gastroesophageal junction cancer, the application of total neoadjuvant chemotherapy according to the FLOT protocol, administered over 8 courses, demonstrated enhanced one-year progression-free survival and improved tolerability of the entire planned treatment regimen.
- Open Access
- 7 September 2022
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 12 (3) , 56-62
BRCA-associated ovarian cancer: a review of the current literature
Ovarian cancer is a heterogeneous disease and is the leading cause of mortality among all gynecological malignancies. The disease is characterized by a high frequency of germline and somatic mutations in BRCA1/2 suppressor genes, which, according to various sources, occur in 10–27 % of all ovarian cancer cases. Determination of mutations in BRCA1 / 2 genes is a mandatory diagnostic criteria and includes performing next generation sequencing. Knowledge of the disease mutational status is important not only in the case of determining treatment plan, but also in the case of prevention of the other malignant neoplasms. The purpose of this review is to summarize the current data on the disease characteristics, diagnosis and treatment of BRCA-associated ovarian cancer. Also, the article presents data from a non-interventional multicenter OvATAR study to assess the prevalence of germline and somatic mutations in BRCA1 / 2 genes in the Russian patient population.
- 7 September 2022
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 12 (3) , 56-62
Open AccessBRCA-associated ovarian cancer: a review of the current literature
Ovarian cancer is a heterogeneous disease and is the leading cause of mortality among all gynecological malignancies. The disease is characterized by a high frequency of germline and somatic mutations in BRCA1/2 suppressor genes, which, according to various sources, occur in 10–27 % of all ovarian cancer cases. Determination of mutations in BRCA1 / 2 genes is a mandatory diagnostic criteria and includes performing next generation sequencing. Knowledge of the disease mutational status is important not only in the case of determining treatment plan, but also in the case of prevention of the other malignant neoplasms. The purpose of this review is to summarize the current data on the disease characteristics, diagnosis and treatment of BRCA-associated ovarian cancer. Also, the article presents data from a non-interventional multicenter OvATAR study to assess the prevalence of germline and somatic mutations in BRCA1 / 2 genes in the Russian patient population.
- Open Access
- 7 August 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 76-86
The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms
In 2019 malignant neoplasms of the female reproductive system (ovarian cancer, (OC), endometrial carcinoma (EC) and cervical cancer (CC) were diagnosed in 58 860 patients – 17.6% of all malignant tumors in women in Russia. The morbidity and mortality rates from these neoplasms remain high over the past 10 years. This article provides a detailed review of the current evidence base for the use of various immunotherapeutic agents in mentioned malignant neoplasms. It has been demonstrated that in relapsed OC (ROC), the only proved indication for immunotherapy is tumors with microsatellite instability (MSI), whereas PD-L1 does not have an independent role in this disease. MSI occurs in approximately 8% of patients with metastatic OC. A significantly higher frequency MSI — up to 25% is detected in metastatic EC. MSI-positive subtype of the disease is characterized by an extremely high sensitivity to immunotherapy - the rate of objective response with pembrolizumab exceeds 50%. For MS-stable EC, the combination of pembrolizumab and lenvatinib is an effective therapeutic option. In advanced CC, on the other hand, PD-L1 has a predictive role for immunotherapy efficacy — the KEYNOTE-158 study showed that about 15% of patients with extensively pretreated metastatic PD-L1-positive CC can achieve long-term remission with pembrolizumab compared to 0% in PD-L1 negative tumors. Current evidence shows that PD-L1 expression can be observed in ≥ 30% of patients.
- 7 August 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 76-86
Open AccessThe role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms
In 2019 malignant neoplasms of the female reproductive system (ovarian cancer, (OC), endometrial carcinoma (EC) and cervical cancer (CC) were diagnosed in 58 860 patients – 17.6% of all malignant tumors in women in Russia. The morbidity and mortality rates from these neoplasms remain high over the past 10 years. This article provides a detailed review of the current evidence base for the use of various immunotherapeutic agents in mentioned malignant neoplasms. It has been demonstrated that in relapsed OC (ROC), the only proved indication for immunotherapy is tumors with microsatellite instability (MSI), whereas PD-L1 does not have an independent role in this disease. MSI occurs in approximately 8% of patients with metastatic OC. A significantly higher frequency MSI — up to 25% is detected in metastatic EC. MSI-positive subtype of the disease is characterized by an extremely high sensitivity to immunotherapy - the rate of objective response with pembrolizumab exceeds 50%. For MS-stable EC, the combination of pembrolizumab and lenvatinib is an effective therapeutic option. In advanced CC, on the other hand, PD-L1 has a predictive role for immunotherapy efficacy — the KEYNOTE-158 study showed that about 15% of patients with extensively pretreated metastatic PD-L1-positive CC can achieve long-term remission with pembrolizumab compared to 0% in PD-L1 negative tumors. Current evidence shows that PD-L1 expression can be observed in ≥ 30% of patients.